Beximco Pharma Is In the Forefront of Industry Developments

Beximco Pharmaceuticals Ltd. has reached another milestone as it won the much reputed Scrip Award recently. The Bangladeshi pharmaceuticals giant has been in the forefront of many progressive developments of the industry. In 2003, the company was the first to introduce anti-retroviral (AVR) drugs in Bangladesh. In 2009, it became the only Bangladeshi company to receive GMP approval from ANSIVA, Brazil. Beximco is also one of the very few and first pharmaceutical companies of Bangladesh to have received approval for export operations to the European and American markets. 

The recent Scrip Award in the category of ‘Best Company in an Emerging Market’ is an award that recognizes individuals and companies that have demonstrated excellent performance towards significant contribution in the healthcare industry. The founders of Beximco, Sohail F Rahman and Salman F Rahman, both prominent Bangladeshi businessmen are positive on the future of the pharmaceuticals industry of Bangladesh, especially on export operations.

Beximco recently signed a MoU with Nuvista pharma to acquire 85.22% shareholding of that company. The acquisition is expected to strengthen Beximco’s presence in the steroid and hormones segment. This is a big boost not only for the company but for the entire economy as a whole. Bangladesh is one of the fastest growing economies; ranked 2nd by the IMF. Export operations being major contributors to this robust growth, the pharmaceuticals industry remains a key contributor. As we know that South East Asia, let alone the other regions, has a huge market for pharmaceutical products, and developments in the industry will definitely serve as a major impetus for the growth of both the industry and the economy.